Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that DSM Biomedical obtained
an exclusive world-wide license for a unique drug & biologics delivery system
developed by MediVas LLC. Integrated into DSM’s Trancerta® Drug Delivery
platform, this will open up a broad range of opportunities for next generation
drug delivery. DSM’s activities in this field are an illustration of the way
DSM is leveraging its competences in Materials Sciences into Life Sciences
applications.